On November 5, 2015 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, reported that three abstracts on the Company’s lead product candidate, BPX-501, an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation, were accepted for poster presentation at the 57th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Bellicum Pharmaceuticals, NOV 5, 2015, View Source;p=RssLanding&cat=news&id=2107373 [SID:1234507980]). The Company will also highlight data in an oral presentation from a preclinical study with its BPX-401 controllable CAR-T (CIDeCAR) product candidate for the treatment of B cell malignancies. The meeting will be held in Orlando, Florida December 5-8, 2015.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor/Analyst Luncheon

Bellicum will also host an investor and analyst luncheon on Monday, December 7, 2015 from 12:15 – 1:15 p.m. EST at the Hyatt Regency Orlando. Management and select key opinion leaders, including lead Principal Investigator, Professor Francesco Locatelli, M.D., will review the BPX-501 Phase 1/2 clinical study data in pediatric patients with hematologic disorders. The luncheon will be webcast live and may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

Full List of ASH (Free ASH Whitepaper) Presentations on Bellicum Programs

BPX-501:

Poster Presentation: "Clinical Outcome after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Results of a Phase I-II Trial"

Abstract Number: 1931
Session Name: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Date: Saturday, December 5, 2015
Presentation Time: 5:30 PM – 7:30 PM EST

Poster Presentation: "Immune Reconstitution after Adoptive Infusion of BPX-501 Cells (donor T cells transduced with iC9 suicide gene) in Children Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT): Preliminary Phenotypic and Functional Results of a Phase I-II Trial"

Abstract Number: 3093
Session Name: 703. Adoptive Immunotherapy: Poster II
Date: Sunday, December 6, 2015
Presentation Time: 6:00 PM – 8:00 PM EST

Poster Presentation: "BPX-501 Cells (donor T cells transduced with iC9 suicide gene) Are Able to Clear Life-Threatening Viral Infections in Children with Primary Immune Deficiencies Given Alpha/Beta T-Cell Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (haplo-HSCT)"

Abstract Number: 4299
Session Name: 703. Adoptive Immunotherapy: Poster III
Date: Monday, December 7, 2015
Presentation Time: 6:00 PM – 8:00 PM EST

Additional data on more BPX-501 patients to be presented at ASH (Free ASH Whitepaper).

BPX-401:

Oral Presentation: "Expression of MyD88/CD40 Drives In Vivo Activation and Proliferation of Chimeric Antigen Receptor-Modified T Cells That Can be Effectively Regulated By Inducible Caspase-9"

Abstract Number: 851
Session Name: 703. Adoptive Immunotherapy: Preclinical Studies
Date: Monday, December 7, 2015
Presentation Time: 5:30 PM EST

BPX-601:

Poster Presentation: "Inducible MyD88/CD40 Allows Rimiducid-Dependent Activation to Control Proliferation and Survival of Chimeric Antigen Receptor-Modified T Cells"

Abstract Number: 4295
Session Name: 703. Adoptive Immunotherapy: Poster III
Date: Monday, December 7, 2015
Presentation Time: 6:00 PM – 8:00 PM EST

Enhanced TCRs:

Poster Presentation: "Inducible MyD88/CD40 Enhances Proliferation and Survival of PRAME-Specific TCR-Engineered T Cells and Increases Anti-Tumor Effects in Myeloma"

Abstract Number: 1886
Session Name: 703. Adoptive Immunotherapy: Poster I
Date: Saturday, December 5, 2015
Presentation Time: 5:30 PM – 7:30 PM EST

Bellicum Program Licensed from Leiden University Medical Center:

Poster Presentation: "T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies"

Abstract Number: 3002
Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II
Date: Sunday, December 6, 2015
Presentation Time: 6:00 PM – 8:00 PM EST